论文部分内容阅读
美国 F DA 已批准了山道士公司的抗组胺药 Tavist-1(富马酸氯马斯丁,clema-stine fumarate)1.34mg 片剂和它的复方产品 Tavist-D(氯马斯丁+苯丙醇胺(p-henypropanolamine)作为非处方药物加以销售。山道士公司认为 Tavist-1和 Tavi-st-D 的批准是处方药物到非处方药物的最大转变。
American F DA has approved Sandoz’s antihistamine Tavist-1 (clema-stine fumarate) 1.34 mg tablet and its compounded product Tavist-D (Chlormastine + Benzene Propanolamine (p-henypropanolamine) is marketed as an over-the-counter drug and Hillstone considers the approval of Tavist-1 and Tavi-st-D to be the biggest shift from prescription to over-the-counter medications.